NB Health Laboratory
Sapporo, Japan· Est.
Japanese biotech developing GPCR-targeted antibodies using its proprietary MoGRAA® Discovery Engine platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese biotech developing GPCR-targeted antibodies using its proprietary MoGRAA® Discovery Engine platform.
Fibrosis
Technology Platform
MoGRAA® Discovery Engine - a proprietary platform for discovering functional monoclonal antibodies specifically targeting G-protein coupled receptors (GPCRs).
Opportunities
Large market potential in GPCR-targeted therapeutics, especially in fibrosis where unmet medical needs exist; potential for platform out-licensing deals with larger pharmaceutical companies.
Risk Factors
Early-stage preclinical pipeline with unproven clinical efficacy; competition from established small molecule GPCR drugs and other biotech companies; dependency on successful fundraising or partnerships for continued development.
Competitive Landscape
Competes in the GPCR drug discovery space against both small molecule developers and other antibody-focused companies; differentiation lies in the MoGRAA® platform's specialization for GPCR-targeted antibodies and claimed advantages in selectivity and duration of action.